Taken together, these results demonstrate that a high expression of PSME1 and PSME2 is positively related with favorable OS, FPS, and PPS in GC patients with most clinicopathological features, while high expression levels of these genes are significantly correlated with poor prognosis in GC patients with 5-FU-based adjuvant treatment. Here, PSME2 is linked to gastric cancer.